April 8, 2013

CAS databases provide millions of journal article references from more than 10,000 major scientific journals worldwide, patent and patent family references from 63 patent authorities around the world, and other reputable web sources.

The following patent record is from the CAplusSM database.


Patent Number: WO 2013003298
Title: Preparation of substituted 2-(imidazo[1,2-a]pyridin-7-yl)-[1,2,4]triazolo[1,5-a]pyrazines as inhibitors of PDE10
Inventor(s): Schmitz, William D.; Debenedetto, Mikkel V.; Kimura, S. Roy
Patent Assignee(s): Bristol-Myers Squibb Company, USA
Source: PCT Int. Appl., 59pp. CODEN: PIXXD2
Language: English

The title compds. I [R = cycloalkyl or II (wherein Q = N or CR1; Q1 = N or CR4; R1-R5 = H, alkoxy, alkyl, etc.); R6 = H, alkyl; X = N, CR7; one of R7 and R8 = H, CN, halo, etc., and the other = (un)substituted III containing 2-4 N atoms (Y = N or CH; Z = N or C); with the proviso], useful as PDE10 inhibitors, were prepared and claimed. E.g., a multi-step synthesis of IV, starting from Me 2-aminoisonicotinate, was described. Exemplified compds. I were tested in the PDE10a inhibition assay (data given for representative compds. I). Compns. comprising compds. I and methods for using the compds. I to inhibit PDE10 are also disclosed.

Please note:  Abstracts and Titles for patent records in CAplus are routinely enhanced to better describe the claimed invention. The title of the PCT publication is Inhibitors of PDE10.

 View the full-text here.

Recent News

    May 22, 2017 | Wiley and CAS Announce
    Collaboration to Deliver Advanced Predictive
    Cheminformatics Capabilities to Researchers

    May 15, 2017 | CAS Powers Research for Charles
    River Laboratories and Top Contract Research
    Organizations Worldwide

    April 10, 2017 | Latest Release of New STN
    Enhances Search History and Expands Database
                                                                      More News >> 

 Media Contact

 Name: Rhonda Ross
 Phone: 614-447-3624                                       
 Email: cas-pr@cas.org